Affiliation:
1. Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II, Institutional Area, Greater
Noida-201306, Uttar Pradesh, India
Abstract
Abstract:
Alzheimer's disease (AD) is an onset and incurable neurodegenerative disorder that has
been linked to various genetic, environmental, and lifestyle factors. Recent research has revealed
several potential targets for drug development, such as the prevention of Aβ production and removal,
prevention of tau hyperphosphorylation, and keeping neurons alive. Drugs that target numerous ADrelated
variables have been developed, and early results are encouraging. This review provides a
concise map of the different receptor signaling pathways associated with Alzheimer's Disease, as
well as insight into drug design based on these pathways. It discusses the molecular mechanisms of
AD pathogenesis, such as oxidative stress, aging, Aβ turnover, thiol groups, and mitochondrial activities,
and their role in the disease. It also reviews the potential drug targets, in vivo active agents, and
docking studies done in AD and provides prospects for future drug development. This review intends
to provide more clarity on the molecular processes that occur in Alzheimer's patient's brains, which
can be of use in diagnosing and preventing the condition.
Publisher
Bentham Science Publishers Ltd.
Reference152 articles.
1. Miran M.; Amirshahrokhi K.; Ajanii Y.; Zadali R.; Rutter M.W.; Enayati A.; Chemical composition, traditional use in medicine,
and pharmacological activities of boswellia sacra flueck Evidence-based Complementary and Alternative Medicine Hindawi Limited 2022,2022
2. Rudnicka E.; Napierała P.; Podfigurna A.; Męczekalski B.; Smolarczyk R.; Grymowicz M.; The World Health Organization (WHO) approach to healthy ageing. Maturitas 2020,139,6-11
3. Bondi M.W.; Edmonds E.C.; Salmon D.P.; Alzheimer’s Disease: Past, present, and future. J Int Neuropsychol Soc 2017,23(9-10),818-831
4. Breijyeh Z.; Karaman R.; Comprehensive review on alzheimer’s disease: Causes and treatment. Molecules 2020,25(24),5789
5. Wong W.; Economic burden of Alzheimer disease and managed care considerations. Am J Manag Care 2020,26(8)(Suppl.),S177-S183